Steven Bloom
About Steven Bloom
Steven Bloom is Chief Business Officer at Werewolf Therapeutics (HOWL), appointed in April 2025; he is age 64 and brings extensive business development, commercial assessment, and corporate strategy expertise across oncology biopharma. His prior roles include CBO positions at Vincerx Pharma, Transgene SA, Boston Pharmaceuticals, and Vavotar Life Sciences, with earlier senior roles in marketing, patient advocacy, and corporate affairs at Eli Lilly. He holds a B.S. from Northeastern University College of Pharmacy . Performance metrics (TSR, revenue/EBITDA growth) specific to his tenure are not disclosed in company filings.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Vincerx Pharma, Inc. | Chief Business Officer | Jul 2023 – Apr 2025 | BD leadership, commercial assessment, corporate strategy in ADC oncology platform |
| Transgene SA | Chief Business Officer | Jan 2022 – Jul 2023 | Led BD for twin platforms in oncolytic viruses and cancer vaccines |
| Boston Pharmaceuticals, Inc. | Chief Business Officer | Jan 2021 – Jan 2022 | CBO for clinical-stage portfolio; partnerships and portfolio strategy |
| Vavotar Life Sciences, LLC | Chief Business Officer | Nov 2019 – Dec 2020 | Oncology-focused BD, corporate development |
| Eli Lilly and Company | Senior roles (marketing, patient advocacy, corporate affairs) | Not specified | Commercial and stakeholder engagement leadership |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| CLL Society (nonprofit) | Chair of the Board | Not specified | Patient education, advocacy, support, and research in CLL/SLL |
Fixed Compensation
- Not disclosed for Steven Bloom. The 2025 proxy covers 2024 named executive officers (Hicklin, Isaacs, Trost) and does not include Bloom, who became an executive after the April 14, 2025 record date .
- No Item 5.02 filing detailing Bloom’s offer letter/compensatory arrangements was found in 2025 filings searched .
Performance Compensation
- Not disclosed for Steven Bloom. Company-wide executive compensation framework includes base salary, annual performance-based cash incentives, and equity (primarily stock options), but the proxy indicates no formal executive ownership guidelines and describes general grant practices; these are not specific to Bloom .
Equity Ownership & Alignment
| As-Of | Shares Owned | Options Exercisable | % of Shares Outstanding |
|---|---|---|---|
| Effective date of appointment (post-Apr 14, 2025) | 0 | 0 | 0.00% (denominator 44,873,646 shares as of Apr 14, 2025) |
- Anti-hedging and pledging: Company policy expressly prohibits short sales, puts/calls, hedging instruments, margin accounts, and pledges—reducing misalignment risk .
- Clawback: Nasdaq-compliant policy to recover excess incentive-based compensation (including stock price/TSR-based awards) for three completed fiscal years preceding an accounting restatement .
- Executive stock ownership guidelines: No formal guidelines applicable to executives per proxy disclosure .
Employment Terms
- No Bloom-specific employment agreement terms disclosed in 2025 filings. Company has employment agreements with other named executives (from 2021) covering severance and change-in-control benefits, but these agreements are not stated to apply to Bloom and should not be inferred .
- Officer compensation is set by the Board per the amended and restated bylaws; no Bloom-specific salary or term provisions disclosed .
Investment Implications
- Alignment: Initial absence of disclosed share ownership and options at appointment suggests limited immediate “skin-in-the-game,” partially offset by strict anti-hedging/pledging and clawback policies that enhance alignment and mitigate risk .
- Retention/insider pressure: Without disclosed grants, vesting schedules, or 10b5-1 plans for Bloom, near-term insider selling pressure appears low; monitor future proxy/8-K disclosures and Form 4s for grant issuance and selling patterns .
- Value creation lever: Bloom’s extensive BD background across oncology platforms indicates potential to advance partnering and registrational pathway work for HOWL’s pipeline (WTX-124/WTX-330/WTX-1011), but filings do not attribute specific achievements to Bloom yet; upcoming 4Q25 clinical updates and FDA interactions are key catalysts to evaluate execution impact .